The Latest News June 16, 2021 argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology Breda, the Netherlands argenx today announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living with generalized myasthenia gravis (gMG). Read argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology More Press Releases News June 1, 2021 argenx to Present at Upcoming Investor Conferences argenx today announced that members of management will participate in the following upcoming investor conferences: Read News May 11, 2021 argenx announces results of Annual General Meeting of Shareholders argenx today announced that the proposed resolutions presented at its Annual General Meeting of Shareholders, held today at 10:00 a.m. CEST, were duly passed. Read News May 7, 2021 argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021 argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Friday, May 14, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its... Read Media center ARGX-118 CIDP Cusatuzumab Efgartigimod Immune Thrombocytopenia Myasthenia Gravis Pemphigus Vulgaris SIMPLE Antibody Platform Facet Tags May 1, 2020 Making Asthma Crystal Clear April 16, 2020 Monoclonal antibodies against GARP/TGF-b1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo April 13, 2020 ARGX-116 / A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels April 8, 2020 Protein crystallization promotes type 2 immunity and is reversible by antibody treatment April 7, 2020 SIMPLE Antibody platform / Combining Somatic Mutations Present in Different in Vivo Affinity-Matured Antibodies Isolated From Immunized Lama Glama Yields Ultra-Potent Antibody Therapeutics Load more
News June 1, 2021 argenx to Present at Upcoming Investor Conferences argenx today announced that members of management will participate in the following upcoming investor conferences: Read
News May 11, 2021 argenx announces results of Annual General Meeting of Shareholders argenx today announced that the proposed resolutions presented at its Annual General Meeting of Shareholders, held today at 10:00 a.m. CEST, were duly passed. Read
News May 7, 2021 argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021 argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Friday, May 14, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its... Read
